Is family history a predictor of response to tumour necrosis factor inhibitors in spondyloarthritis? A Swedish nationwide cohort study

References

• Ash Z, Gaujoux-Viala C, Gossec L, Hensor EMA, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J, Cantini F, et al. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford) 2014;54:1210–19.
   PubMed Web of Science ®Google Scholar
• Ornbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, et al. Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis 2019;78:1536–44.
   PubMed Web of Science ®Google Scholar
• Brahe CH, Ornbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford) 2020;59:1640–50.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364–9.
   PubMed Web of Science ®Google Scholar
• Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P, Khmelinskii N, Cruz-Machado R, Rocha TM, et al. Real-world long-term effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the rheumatic diseases Portuguese register. J Rheumatol 2020;47:690–700.
   PubMed Web of Science ®Google Scholar
• Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011;13:R94.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Szumski A, Koenig AS, Jones H. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum 2019;48:997–1004.
   PubMed Web of Science ®Google Scholar
• Davis JC Jr., Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751–4.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002–8.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010;62:1362–9.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801–8.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Højgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford) 2015;55:659–68.
   PubMed Web of Science ®Google Scholar
• Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, et al. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 2017;19:164.
   PubMed Web of Science ®Google Scholar
• Yahya F, Gaffney K, Hamilton L, Lonsdale E, Leeder J, Brooksby A, et al. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort. Rheumatology (Oxford) 2018;57:619–24.
   PubMed Web of Science ®Google Scholar
• Morin M, Hellgren K, Frisell T. Familial aggregation and heritability of ankylosing spondylitis - a Swedish nested case-control study. Rheumatology (Oxford) 2020;59:1695–702.
   PubMed Web of Science ®Google Scholar
• Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000;59:883–6.
   PubMed Web of Science ®Google Scholar
• Geirsson AJ, Kristjansson K, Gudbjornsson B. A strong familiality of ankylosing spondylitis through several generations. Ann Rheum Dis 2010;69:1346–8.
   PubMed Web of Science ®Google Scholar
• Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007;56:2633–9.
   PubMedGoogle Scholar
• Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SMA, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009;68:664–7.
   PubMed Web of Science ®Google Scholar
• Karason A, Love TJ, Gudbjornsson B. A strong heritability of psoriatic arthritis over four generations–the Reykjavik Psoriatic Arthritis Study. Rheumatology (Oxford) 2009;48:1424–8.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32:181–99.
   PubMed Web of Science ®Google Scholar
• Myers A, Kay LJ, Lynch SA, Walker DJ. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology (Oxford) 2005;44:773–6.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classiication criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
   PubMed Web of Science ®Google Scholar
• Almodovar R, Font P, Zarco-Montejo P, Collantes E, Mulero J, Gratacos J, et al. Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). Clin Exp Rheumatol 2011;29:822–7.
   PubMed Web of Science ®Google Scholar
• Almodovar R, Navarro-Compan V, Fernandez-Carballido C, Hernandez A, De Miguel E, Zarco P. Differences between familial and sporadic early spondyloarthritis: results from the ESPERANZA cohort. Clin Exp Rheumatol 2016;34:575–80.
   PubMed Web of Science ®Google Scholar
• Rahman P, Schentag CT, Beaton M, Gladman DD. Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis. Clin Exp Rheumatol 2000;18:7–12.
   PubMed Web of Science ®Google Scholar
• Solmaz D, Bakirci S, Kimyon G, Gunal EK, Dogru A, Bayindir O, et al. Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res (Hoboken) 2020;72:63–8.
   PubMed Web of Science ®Google Scholar
• Joshi R, Reveille JD, Brown MA, Weisman MH, Ward MM, Gensler LS, et al. Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012;64:780–4.
   PubMed Web of Science ®Google Scholar
• Paardt M, Dijkmans B, Giltay E, van der Horst-bruinsma I. Dutch patients with familial and sporadic ankylosing spondylitis do not differ in disease phenotype. J Rheumatol 2002;29:2583–4.
   PubMed Web of Science ®Google Scholar
• Calin A, Gail Kennedy L, Edmunds L, Will R. Familial versus sporadic ankylosing spondylitis. two different diseases? Arthritis Rheum 1993;36:676–81.
   PubMedGoogle Scholar
• Kim HW, Choe HR, Lee SB, Chang WI, Chae HJ, Moon JY, et al. Phenotype difference between familial and sporadic ankylosing spondylitis in Korean patients. J Korean Med Sci 2014;29:782–7.
   PubMed Web of Science ®Google Scholar
• Alazmi M, Sari I, Krishnan B, Inman RD, Haroon N. Profiling response to tumor necrosis factor inhibitor treatment in axial spondyloarthritis. Arthritis Care Res (Hoboken) 2018;70:1393–9.
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Askling J, Arkema EV. The Swedish rheumatology quality register: optimisation of rheumatic disease assessments using register-enriched data. Clin Exp Rheumatol 2014;32(Suppl 85):S–147–9.
   Web of Science ®Google Scholar
• Wadstrom H, Eriksson JK, Neovius M, Askling J. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? Scand J Rheumatol 2015;44:22–8.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726–35.
   PubMed Web of Science ®Google Scholar
• Lindstrom U, Exarchou S, Sigurdardottir V, Sundstrom B, Askling J, Eriksson JK, et al. Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register. Scand J Rheumatol 2015;44:369–76.
   PubMed Web of Science ®Google Scholar
• Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden–a population-based register study. PLoS One 2014;9:e98024.
   PubMed Web of Science ®Google Scholar
• Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsblad D, Elia H, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 2017;76:1515–21.
   PubMed Web of Science ®Google Scholar
• Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis 2013;72:578–82.
   PubMed Web of Science ®Google Scholar
• Frisell T, Saevarsdottir S, Askling J. Does a family history of RA influence the clinical presentation and treatment response in RA? Ann Rheum Dis 2016;75:1120–5.
   PubMed Web of Science ®Google Scholar
• Krabbe S, Glintborg B, Østergaard M, Hetland ML. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis. Scand J Rheumatol 2019;48:128–32.
   PubMed Web of Science ®Google Scholar
• Jakobsson GL, Sternegård E, Olén O, Myrelid P, Ljung R, Strid H, et al. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol 2017;52:216–21.
   PubMed Web of Science ®Google Scholar
• Waldenlind K, Eriksson JK, Grewin B, Askling J. Validation of the rheumatoid arthritis diagnosis in the Swedish National Patient Register: a cohort study from Stockholm County. BMC Musculoskelet Disord 2014;15:432.
   PubMed Web of Science ®Google Scholar